Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Semaglutide (Primary) ; Semaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 17 Oct 2017 Results comparing efficacy of oral semaglutide with placebo, published in the JAMA: the Journal of the American Medical Association.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.